These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33768011)

  • 1. Computational Design of gRNAs Targeting Genetic Variants Across HIV-1 Subtypes for CRISPR-Mediated Antiviral Therapy.
    Chung CH; Allen AG; Atkins A; Link RW; Nonnemacher MR; Dampier W; Wigdahl B
    Front Cell Infect Microbiol; 2021; 11():593077. PubMed ID: 33768011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics.
    Dampier W; Sullivan NT; Mell JC; Pirrone V; Ehrlich GD; Chung CH; Allen AG; DeSimone M; Zhong W; Kercher K; Passic S; Williams JW; Szep Z; Khalili K; Jacobson JM; Nonnemacher MR; Wigdahl B
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):950-960. PubMed ID: 29968495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing broad-spectrum anti-HIV-1 gRNAs to target patient-derived variants.
    Dampier W; Sullivan NT; Chung CH; Mell JC; Nonnemacher MR; Wigdahl B
    Sci Rep; 2017 Oct; 7(1):14413. PubMed ID: 29089503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of HIV-1 Genetic Diversity on CRISPR-Cas9 Antiviral Activity and Viral Escape.
    Darcis G; Binda CS; Klaver B; Herrera-Carrillo E; Berkhout B; Das AT
    Viruses; 2019 Mar; 11(3):. PubMed ID: 30871200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.
    Roychoudhury P; De Silva Feelixge H; Reeves D; Mayer BT; Stone D; Schiffer JT; Jerome KR
    BMC Biol; 2018 Jul; 16(1):75. PubMed ID: 29996827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel gRNA design pipeline to develop broad-spectrum CRISPR/Cas9 gRNAs for safe targeting of the HIV-1 quasispecies in patients.
    Sullivan NT; Dampier W; Chung CH; Allen AG; Atkins A; Pirrone V; Homan G; Passic S; Williams J; Zhong W; Kercher K; Desimone M; Li L; C Antell G; Mell JC; Ehrlich GD; Szep Z; Jacobson JM; Nonnemacher MR; Wigdahl B
    Sci Rep; 2019 Nov; 9(1):17088. PubMed ID: 31745112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 System with Dual gRNAs Synergically Inhibit Hepatitis B Virus Replication.
    Fei L; Sun S; Yang Q; Huang Y; Li Q; Tao S; Chen L
    Discov Med; 2024 Jun; 36(185):1169-1179. PubMed ID: 38926103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination.
    Herskovitz J; Hasan M; Patel M; Blomberg WR; Cohen JD; Machhi J; Shahjin F; Mosley RL; McMillan J; Kevadiya BD; Gendelman HE
    EBioMedicine; 2021 Nov; 73():103678. PubMed ID: 34774454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR Genome Editing Made Easy Through the CHOPCHOP Website.
    Labun K; Krause M; Torres Cleuren Y; Valen E
    Curr Protoc; 2021 Apr; 1(4):e46. PubMed ID: 33905612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host Double Strand Break Repair Generates HIV-1 Strains Resistant to CRISPR/Cas9.
    Yoder KE; Bundschuh R
    Sci Rep; 2016 Jul; 6():29530. PubMed ID: 27404981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS.
    Yin C; Zhang T; Li F; Yang F; Putatunda R; Young WB; Khalili K; Hu W; Zhang Y
    AIDS; 2016 May; 30(8):1163-74. PubMed ID: 26990633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR-gRNA Design.
    Pallarès Masmitjà M; Knödlseder N; Güell M
    Methods Mol Biol; 2019; 1961():3-11. PubMed ID: 30912036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiplexed
    Ophinni Y; Miki S; Hayashi Y; Kameoka M
    Viruses; 2020 Oct; 12(11):. PubMed ID: 33126728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing Heritable Mutations in Arabidopsis thaliana Using a Modified CRISPR/Cas9 Toolkit Comprising PAM-Altered Cas9 Variants and gRNAs.
    Yamamoto A; Ishida T; Yoshimura M; Kimura Y; Sawa S
    Plant Cell Physiol; 2019 Oct; 60(10):2255-2262. PubMed ID: 31198958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape.
    Wang G; Zhao N; Berkhout B; Das AT
    Mol Ther; 2016 Mar; 24(3):522-6. PubMed ID: 26796669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SeqCor: correct the effect of guide RNA sequences in clustered regularly interspaced short palindromic repeats/Cas9 screening by machine learning algorithm.
    Liu X; Yang Y; Qiu Y; Reyad-Ul-Ferdous M; Ding Q; Wang Y
    J Genet Genomics; 2020 Nov; 47(11):672-680. PubMed ID: 33451939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape.
    Lebbink RJ; de Jong DC; Wolters F; Kruse EM; van Ham PM; Wiertz EJ; Nijhuis M
    Sci Rep; 2017 Feb; 7():41968. PubMed ID: 28176813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational Prediction of CRISPR/Cas9 Target Sites Reveals Potential Off-Target Risks in Human and Mouse.
    Wang Q; Ui-Tei K
    Methods Mol Biol; 2017; 1630():43-53. PubMed ID: 28643248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic gRNA/Cas9 Ribonucleoprotein Inhibits HIV Reactivation and Replication.
    Khanal S; Cao D; Zhang J; Zhang Y; Schank M; Dang X; Nguyen LNT; Wu XY; Jiang Y; Ning S; Zhao J; Wang L; Gazzar ME; Moorman JP; Yao ZQ
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.